Exact Sciences CEO Kevin Conroy's 2020 pay rises 8% to $20M

Exact Sciences reports 2020 executive compensation

By ExecPay News

Published: April 29, 2021

Exact Sciences reported fiscal year 2020 executive compensation information on April 29, 2021.
In 2020, seven executives at Exact Sciences received on average a compensation package of $5.8M, a 20% decrease compared to previous year.
Average pay of disclosed executives at Exact Sciences
Kevin T. Conroy, Chief Executive Officer, received $20M in total, which increased by 8% compared to 2019. 61% of Conroy's compensation, or $12M, was in stock awards. Conroy also received $1.4M in bonus, $6M in option awards, $499K in salary, as well as $46K in other compensation.
For fiscal year 2020, the median employee pay was $110,616 at Exact Sciences. Therefore, the ratio of Kevin T. Conroy's pay to the median employee pay was 182 to one.
Gisela Paulsen, Former General Manager, Precision Oncology, received a compensation package of $5.8M. 88% of the compensation package, or $5.1M, was in stock awards.
Mark Stenhouse, Former General Manager, Screening, earned $3.3M in 2020, a 40% decrease compared to previous year.
Graham P. Lidgard, Chief Scientific Officer, received $3.2M in 2020, which decreases by 37% compared to 2019.
Jeffrey T. Elliott, Chief Financial Officer, earned $3.2M in 2020, a 38% decrease compared to previous year.
D. Scott Coward, Chief Administrative Officer, received $3.1M in 2020, which decreases by 38% compared to 2019.
Jacob Orville, General Manager, Pipeline, earned $1.8M in 2020, a 55% decrease compared to previous year.

Related executives

Kevin Conroy

Exact Sciences

Chief Executive Officer

Jeffrey Elliott

Exact Sciences

Chief Financial Officer

D Coward

Exact Sciences

Chief Administrative Officer

Graham Lidgard

Exact Sciences

Chief Scientific Officer

Jacob Orville

Exact Sciences

General Manager, Pipeline

Mark Stenhouse

Exact Sciences

Former General Manager, Screening

Gisela Paulsen

Exact Sciences

Former General Manager, Precision Oncology

You may also like

Source: SEC filing on April 29, 2021.